Our findings indicate that KCND2 demonstrates a moderate association with VEGF targets, a slight association with immunotherapeutic targets, while KCND2 might not directly impact HER2‐related pathways in GC (Table S1). This evidence concerns the gene VEGFA and gastric cancer.